Showing 2961-2970 of 10546 results for "".
How to Deal with Hagglers and Other Tough Patients
https://practicaldermatology.com/topics/practice-management/how-to-deal-with-hagglers-and-other-tough-patients/19211/Michael J. Sacopulos, JD offers strategies for handling difficult patients and how to negotiate with hagglers.Hoya ConBio - The Medlite Peel
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/hoya-conbio-the-medlite-peel/19455/A specific patient case is demonstrated to show the outcome of using the Medlite as a laser peel. Valuable tips and suggestions are given by Dr. Brian Rubach.Hoya ConBio - Laser Assisted Hair Reduction
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/hoya-conbio-laser-assisted-hair-reduction/19461/Video demonstrations on the different settings to use for laser assisted hair reduction.BroadBand Light BBL - Patient Testimonials
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/broadband-light-bbl-patient-testimonials/19466/Patients describe their experience with sciton BroadBand Light (BBL).June Issue: Melanoma Updates - Epidemiology, Diagnostics, and Treatment
https://practicaldermatology.com/issues/may-june-2025/melanoma-updates-epidemiology-diagnostics-and-treatment/35917/In this article, we review the latest changes in melanoma incidence and mortality, highlight key disparities among minority populations, and summarize emerging trends in technology and treatment that are reshaping the future of melanoma care.FDA Approval for Delgocitinib
https://practicaldermatology.com/series/c-suite-chats/fda-approval-for-delgocitinib/36650/Robert Spurr, EVP, North America for LEO Pharma, discusses the importance of an FDA-approved option for treating moderate-to-severe chronic hand eczema in adults.The Impact of Clascoterone Topical Cream, 1%: The US Experience 4 Years After Approval and Clinical Expectations for Acne Patients in Other Regions of the World
https://practicaldermatology.com/topics/acne-rosacea/Impact-Clascoterone-Topical-Cream/32830/Clascoterone topical cream, 1% (Winlevi), approved by the US Food and Drug Administration (FDA) in 2020 as the first novel drug introduced for the treatment of acne vulgaris since 1982, is indicated in the US for patients 12 years of age and older. The safety and efficacy were supported by two succeVtama Approved for AD in Adults and Children
https://practicaldermatology.com/series/dermwire-tv/vtama-approved-ad-adults-and-children/30079/In this week's DermwireTV, the FDA approves Vtama (tapinarof cream 0.1%) for atopic dermatitis in adults and children; the FDA approves Nemluvio (nemolizumab) for moderate-to-severe AD; and the president of Nuance Medical discusses the acquisition of scar treatment brand, Biocorneum.DermWireTV: Olumiant Approved for AA; Radiesse + Launch; Derms as Influencers; VCS
https://practicaldermatology.com/topics/practice-management/dermwiretv-olumiant-approved-for-aa-radiesse-launch-derms-as-influencers-vcs/20107/Olumiant (baricitinib) from Eli Lilly and Company is approved to treat adult patients with severe alopecia areata. Dermatologists rank as top influencers of consumers’ decisions to have cosmetic procedures, according to results of the American Society for Dermatologic Surgery (ASDS) Consumer SurveyFive ways to market for the “next normal”
https://practicaldermatology.com/topics/practice-management/five-ways-to-market-for-the-next-normal/20015/You’ve heard it time and time again. The “new normal.” We have been living and working within this new environment for almost two years. In this Ekwa Marketing video, we ask, “What is the next normal?” We isolate five ways to market for tomorrow’s increasingly digitally savvy, curious, socially awar